Literature DB >> 33968687

Can we still consider thyroid hyperfunction a protective condition for the onset of thyroid cancer?

Elena Bonati1, Stefania Bettoni1, Tommaso Loderer1, Paolo Del Rio1.   

Abstract

BACKGROUND: Thyroid cancer is the ninth most commonly diagnosed cancer in the world, and the most common endocrine carcinoma. It was originally believed to be a rare event in patients with thyroid hyperfunction and it was reported that hyperthyroidism had a protective role against thyroid neoplasms. However, in recent years, several studies have hypothesized that differentiated thyroid carcinomas and hyperthyroidism may coexist. Our study aims therefore to evaluate the incidence of differentiated thyroid carcinomas on definitive histological examination, in patients undergoing total thyroidectomy or hemithyroidectomy with coexisting hyperfunctioning thyroid disease, to understand whether hyperthyroidism can be considered a protective condition against the onset of thyroid neoplasms.
METHODS: The study involved 1,449 patients underwent to thyroid surgery from 2010 to 2018 at the General Surgery Unit, Department of Surgery, University Hospital of Parma, Parma, Italy, presenting thyroid cancer at postoperative histological exam. Patients were divided in two groups based on the presence (Group A) or absence (Group B) of hyperfunction. All data were collected in a dedicated database and include demographic data, such as age and sex, preoperative cytology, date and type of surgery, postoperative diagnosis, characteristics of aggressiveness of the neoplasm and postoperative complications. For data analysis, a P value of less than 0.05 was considered statistically significant.
RESULTS: The incidence of thyroid carcinomas was lower in patients suffering from hyperfunction compared to the incidence found in non-hyperthyroid patients, both in preoperative cytological examination and in postoperative diagnosis through histological examination. Furthermore, the tumors that have developed in patients with hyperfunction had a comparable degree of aggression and invasiveness in the two groups studied. However, we have found an equal incidence of microcarcinomas and occult carcinomas on postoperative histological examination. Postoperative complications in patients with cancer were similar, regardless of the presence or absence of hyperfunctioning thyroid disease.
CONCLUSIONS: Our study confirms that hyperthyroidism is a protective condition against thyroid carcinoma, but the finding of an equivalent incidence of occult carcinomas in the two groups stresses the need to perform a cytological examination in case of a nodular pathology in a hyperthyroid patient before performing a treatment. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Thyroid; hyperthyroidism; microcarcinoma; occult carcinoma; thyroid cancer

Year:  2021        PMID: 33968687      PMCID: PMC8102229          DOI: 10.21037/gs-20-688

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  28 in total

1.  Hyperthyroidism and concurrent thyroid carcinoma.

Authors:  M Ruggieri; F Scocchera; M Genderini; A Mascaro; B Luongo; A Paolini
Journal:  Eur Rev Med Pharmacol Sci       Date:  1999 Nov-Dec       Impact factor: 3.507

Review 2.  Thyroid carcinoma in Graves' disease: A meta-analysis.

Authors:  Joy U L Staniforth; Senarath Erdirimanne; Guy D Eslick
Journal:  Int J Surg       Date:  2015-11-26       Impact factor: 6.071

Review 3.  Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia.

Authors:  O Edafe; R Antakia; N Laskar; L Uttley; S P Balasubramanian
Journal:  Br J Surg       Date:  2014-01-09       Impact factor: 6.939

4.  The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer.

Authors:  S Filetti; A Belfiore; S M Amir; G H Daniels; O Ippolito; R Vigneri; S H Ingbar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

5.  Hypocalcaemia after total thyroidectomy for Graves' disease and for benign atoxic multinodular goitre.

Authors:  Páll Hallgrimsson; E Nordenström; A Bergenfelz; M Almquist
Journal:  Langenbecks Arch Surg       Date:  2012-09-14       Impact factor: 3.445

6.  Incidental Thyroid cancer in patients undergoing surgery for hyperthyroidism.

Authors:  Yogesh More; Aly Bernard Khalil; Huda Mustafa; Manjiri Gupte; Musa Al-Abbadi; Doua Elamin; Luaay Aziz; Shaik Irfan Basha
Journal:  Am J Otolaryngol       Date:  2019-03-11       Impact factor: 1.808

7.  Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter?

Authors:  Kellen C Welch; Christopher R McHenry
Journal:  J Surg Res       Date:  2011-04-19       Impact factor: 2.192

8.  Thyroid carcinoma in Graves' disease.

Authors:  L M Farbota; D B Calandra; A M Lawrence; E Paloyan
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

9.  [Surgical Diagnosis and Treatment of Primary Hyperthyroidism Complicated with Occult Thyroid Carcinoma].

Authors:  Xin Wu; Jian-chun Yu; Wei-ming Kang; Zhi-qiang Ma; Xin Ye
Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao       Date:  2015-08

10.  Thyroid carcinoma risk in patients with hyperthyroidism and role of preoperative cytology in diagnosis.

Authors:  K Gul; A Di Ri Koc; G Ki Yak; P E Ersoy; N S Ugras; D Ozdemi; R Ersoy; B Cakir
Journal:  Minerva Endocrinol       Date:  2009-12       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.